← Human Trials & Peer-Reviewed Studies
Effects of pyridostigmine, corticotropin-releasing hormone and growth hormone-releasing hormone on the pituitary-adrenal axis and on growth hormone secretion in dementia
Plain-language guide to PMID 8272199 (1993): clinical trial study of GHRH (Growth Hormone-Releasing Hormone) and ACTH (Corticotropin) in 7 patients.
Key Facts
- PMID
- 8272199
- Journal
- Neuropsychobiology
- Year
- 1993
- Study type
- Clinical Trial
- Authors
- Murialdo G et al. (10 authors)
- DOI
- 10.1159/000119020
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of GHRH (Growth Hormone-Releasing Hormone) and ACTH (Corticotropin), published as a clinical trial.
Alterations of neuroendocrinological indices determined by the impaired regulating effects of cholinergic neurotransmission have been described in primary dementia.
In this study the researchers have evaluated the effects of acetylcholinesterase inhibition by pyridostigmine on growth hormone (GH), adrenocorticotropic hormone (ACTH) and cortisol secretion and on their responses to GH-releasing hormone (GHRH) and corticotropin-releasing hormone (CRH) in 7 patients with primary degenerative dementia and in 8 sex- and age-matched controls.
Who Took Part
The abstract describes 7 patients taking part.
PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.
What Was Measured
Alterations of neuroendocrinological indices determined by the impaired regulating effects of cholinergic neurotransmission have been described in primary dementia.
In this study the researchers have evaluated the effects of acetylcholinesterase inhibition by pyridostigmine on growth hormone (GH), adrenocorticotropic hormone (ACTH) and cortisol secretion and on their responses to GH-releasing hormone (GHRH) and corticotropin-releasing hormone (CRH) in 7 patients with primary degenerative dementia and in 8 sex- and age-matched controls.
Topics PubMed links to this paper include Adrenocorticotropic Hormone, Corticotropin-Releasing Hormone, Dementia, Growth Hormone, Growth Hormone-Releasing Hormone, Hydrocortisone and Pituitary-Adrenal System.
What This Means in Plain Language
This is a clinical trial of GHRH (Growth Hormone-Releasing Hormone) and ACTH (Corticotropin) in 7 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1993 (Neuropsychobiology), a journal based in Switzerland.
More context: the GHRH (Growth Hormone-Releasing Hormone) compound page and the ACTH (Corticotropin) compound page, all human trials.
Our Notes on the Compounds
GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.
ACTH (Corticotropin): The 39-amino-acid pituitary hormone that drives cortisol production; given as repository corticotropin (Acthar Gel).
CRH (Corticotropin-Releasing Hormone): The 41-amino-acid hypothalamic hormone that triggers ACTH release; corticorelin is used diagnostically.
Related Pages
- GHRH (Growth Hormone-Releasing Hormone) in the library
- ACTH (Corticotropin) in the library
- CRH (Corticotropin-Releasing Hormone) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.